Xbrane Biopharma AB (XBRANE) Stock Overview

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a biosimilar candidate for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, and axial spondylitis; Xdivane for skin cancer, lung cancer, renal cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xtrudane for brain cancer, melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane for multiple melanoma. Xbrane Biopharma AB (publ) was incorporated in 2008 and is headquartered in Solna, Sweden.